TERIFLUNOMIDE tablet, film coated
For Healthcare Providers >

1. Patient Information
2. Issued On:
3. For Men Taking Teriflunomide Tablets:
4. Do Not Take Teriflunomide If You:
5. Teriflunomide Tablets?
6. The Most Common Side Effects Of Teriflunomide Tablets Include:
7. What Are The Ingredients In Teriflunomide Tablets?
8. Harm To Your Unborn Baby:
9. What Is Teriflunomide Tablet?
10. Especially Tell Your Doctor If You Take Medicines That Could Raise Your Chance Of Getting Infections, Including Medicines Used To Treat Cancer Or To Control Your Immune System.ask Your Doctor Or Pharmacist For A List Of These Medicines If You Are Not Sure.know The Medicines You Take. Keep A List Of Them To Show Your Doctor Or Pharmacist When You Get A New Medicine.how Should I Take Teriflunomide Tablets?
11. What Are Possible Side Effects Of Teriflunomide Tablets?
12. How Should I Store Teriflunomide Tablets?
13. Liver Problems:
14. Call Your Doctor Right Away If You Have Any Of The Following Symptoms Of Liver Problems:
15. What Are Teriflunomide Tablets?
16. Do Not Take Teriflunomide Tablets If You:
17. What Should I Tell My Doctor Before Taking Teriflunomide Tablets?
18. How Should I Take Teriflunomide Tablets?
19. Manufactured By:
20. Manufactured For:

Patient Information ⮝

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

A Medication Guide is required for distribution with teriflunomide tablets.

Hepatotoxicity

Inform patients that teriflunomide may increase liver enzymes and that their liver enzymes will be checked before starting teriflunomide and for at least 6 months while they are taking teriflunomide. Advise patients that they should contact their physician if they have any unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.

Importance of Preventing Pregnancy

• Inform patients that based on animal studies, teriflunomide may cause fetal harm.
• Advise females of reproductive potential of the need for effective contraception during teriflunomide treatment and until completion of an accelerated elimination procedure. Advise them that an accelerated elimination procedure can be used at any time after the discontinuation of teriflunomide.
• Instruct the patient that if she suspects or confirms pregnancy, she should immediately inform her physician.
• Instruct men taking teriflunomide and not wishing to father a child to use effective contraception to minimize any possible risk to the fetus; their female partners should also use effective contraception.
• Advise men wishing to father a child to discontinue use of teriflunomide and undergo an accelerated elimination procedure.

Availability of an Accelerated Elimination Procedure

Advise patients that teriflunomide may stay in the blood for up to 2 years after the last dose and that an accelerated elimination procedure may be used if needed.

Risk of Infections

Inform patients that they may develop a lowering of their white blood cell counts and that their blood counts will be checked before starting teriflunomide.

Inform patients that they may be more likely to get infections when taking teriflunomide and that they should contact their physician if they develop symptoms of infection, particularly in case of fever.

Advise patients that the use of some vaccines should be avoided during treatment with teriflunomide and for at least 6 months after discontinuation.

Serious Allergic Reactions

Advise patients to discontinue teriflunomide and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur[SeeContraindications (4)andWarnings and Precautions (5.5)].Signs and symptoms include dyspnea, urticaria, and angioedema including lips, eyes, throat, and tongue or skin rash.

Peripheral Neuropathy

Inform patients that they may develop peripheral neuropathy. Advise patients that they should contact their physician if they develop symptoms of peripheral neuropathy, such as numbness or tingling of hands or feet.

Increased Blood Pressure

Inform patients that teriflunomide may increase blood pressure.

Lactation
Inform patients that it is not known whether this drug is present in human milk. Advise patients, if they are considering breastfeeding, to discuss this with their healthcare provider to decide if they will take teriflunomide or breastfeed. Advise patients that they should not do both.

Manufactured by:
MSN Laboratories Private Limited
Mahabubnagar (Dt.)
Telangana 509 216,
INDIA

Distributed by:
MSN Pharmaceuticals Inc.
Edison, NJ 08837

Issued On: ⮝

May 2019

For Men Taking Teriflunomide Tablets: ⮝

• If your female partner plans to become pregnant, you should stop taking teriflunomide tablets and ask your doctor how to quickly lower the levels of teriflunomide tablets in your blood.
• If your female partner does not plan to become pregnant, you and your female partner should use effective birth control during your treatment with teriflunomide tablets. Teriflunomide remains in your blood after you stop taking it, so continue using effective birth control until teriflunomide blood levels have been checked and they are low enough.

Teriflunomide may stay in your blood for up to 2 years after you stop taking it. Your doctor can prescribe a medicine to help lower your blood levels of teriflunomide more quickly. Talk to your doctor if you want more information about this.

Do Not Take Teriflunomide If You: ⮝

• have had an allergic reaction to teriflunomide tablets or a medicine called leflunomide
• have severe liver problems
• are pregnant or are of childbearing age and not using effective birth control
• take a medicine called leflunomide

Teriflunomide Tablets? ⮝

Teriflunomide tabletsmay cause serious side effects, including:

• decreases in your white blood cell count.Your white blood cell counts should be checked before you start taking teriflunomide tablets. When you have a low white blood cell count you:

• may have more frequent infections.You should have a skin test for TB (tuberculosis) before you start taking teriflunomide tablets. Tell your doctor if you have any of these symptoms of an infection:
  • fever
  • tiredness
  • body aches
  • chills
  • nausea
  • vomiting
• should not receive certain vaccinations during your treatmentwith teriflunomide tablets and for 6 months after your treatment with teriflunomide tablets ends.

• numbness or tingling in your hands or feet that is different from your MS symptoms.You have a greater chance of getting peripheral neuropathy if you:
  • are over 60 years of age
  • take certain medicines that affect your nervous system
  • have diabetes

  Tell your doctor if you have numbness or tingling in your hands or feet that is different from your MS.

• Allergic reactions, including serious skin problems.Tell your doctor if you have difficulty breathing, itching, swelling on any part of your body including in your lips, eyes, throat or tongue, or any skin problems such as rash or redness and peeling.
• new or worsening breathing problems.Tell your doctor if you have shortness of breath or coughing with or without fever.
• high blood pressure.Your doctor should check your blood pressure before you start taking teriflunomide tablets and while you are taking teriflunomide tablets.

The Most Common Side Effects Of Teriflunomide Tablets Include: ⮝

• headache
• diarrhea
• nausea
• hair thinning or loss (alopecia)
• increases in the results of blood tests to check your liver function

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of teriflunomide tablets. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-332-1088.

How should I store

What Are The Ingredients In Teriflunomide Tablets? ⮝

Active ingredient: teriflunomide

Inactive ingredients in 7 mg and 14 mg tablets: corn starch, hydroxypropyl cellulose, lactose monohydrate, microcrystalline cellulose, magnesium stearate and sodium starch glycolate. The film coating for the 7 mg and 14 mg tablet is made of colloidal anhydrous silica, FD & C Blue # 2/indigo carmine aluminum lake, hypromellose, polyethylene glycol, titanium dioxide and in addition to these, the 7 mg tablet film coating includes iron oxide yellow.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Amneal Pharmaceuticals Pvt. Ltd.
Oral Solid Dosage Unit
Ahmedabad 382213, INDIA

Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807

Rev. 09-2019-01

Harm To Your Unborn Baby: ⮝

Teriflunomide tablets may cause harm to your unborn baby. Do not take teriflunomide tablets if you are pregnant. Do not take teriflunomide tablets unless you are using effective birth control.

• If you are a female, you should have a pregnancy test before you start taking teriflunomide tablets. Use effective birth control during your treatment with teriflunomide tablets.
• After stopping teriflunomide tablets, continue using effective birth control until you have blood tests to make sure your blood levels of teriflunomide tablets are low enough. If you become pregnant while taking teriflunomide tablets or within 2 years after you stop taking it, tell your doctor right away.
• For men taking teriflunomide tablets:
  • If your female partner plans to become pregnant, you should stop taking teriflunomide tablets and ask your doctor how to quickly lower the levels of teriflunomide tablets in your blood.
  • If your female partner does not plan to become pregnant, you and your female partner should use effective birth control during your treatment with teriflunomide tablets. Teriflunomide tablets remains in your blood after you stop taking it, so continue using effective birth control until teriflunomide tablets blood levels have been checked and they are low enough.

Teriflunomide tabletsmay stay in your blood for up to 2 years after you stop taking it. Your doctor can prescribe a medicine to help lower your blood levels of teriflunomide tablets more quickly. Talk to your doctor if you want more information about this.

What Is Teriflunomide Tablet? ⮝

Teriflunomide tablet is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS). Teriflunomide tablets can decrease the number of MS flare-ups (relapses). Teriflunomide tablet does not cure MS, but it can help slow down the physical problems that MS causes.

It is not known if teriflunomide tablet is safe and effective in children.

Especially Tell Your Doctor If You Take Medicines That Could Raise Your Chance Of Getting Infections, Including Medicines Used To Treat Cancer Or To Control Your Immune System.ask Your Doctor Or Pharmacist For A List Of These Medicines If You Are Not Sure.know The Medicines You Take. Keep A List Of Them To Show Your Doctor Or Pharmacist When You Get A New Medicine.how Should I Take Teriflunomide Tablets? ⮝

• Take teriflunomide tablets exactly as your doctor tells you to take it.
• Take teriflunomide tablets 1 time each day.
• Take teriflunomide tablets with or without food.

What Are Possible Side Effects Of Teriflunomide Tablets? ⮝

Teriflunomide tablets may cause serious side effects, including:

• decreases in your white blood cell count.Your white blood cell counts should be checked before you start taking teriflunomide tablets. When you have a low white blood cell count you:
  • may have more frequent infections.You should have a skin test for TB (Tuberculosis) before you start taking teriflunomide tablets. Tell your doctor if you have any of these symptoms of an infection:
    • fever
    • tiredness
    • body aches
    • chills
    • nausea
    • vomiting
  • should not receive certain vaccinations during your treatmentwith teriflunomide tablets and for 6 months after your treatment with teriflunomide tablets ends.

• numbness or tingling in your hands or feet that is different from your MS symptoms.You have a greater chance of getting peripheral neuropathy if you:

  • are over 60 years of age
  • take certain medicines that affect your nervous system
  • have diabetes

Tell your doctor if you have numbness or tingling in your hands or feet that is different from your MS.

• Allergic reactions, including serious skin problems.Tell your doctor if you have difficulty breathing, itching, swelling on any part of your body including in your lips, eyes, throat or tongue, or any skin problems such as rash or redness and peeling.
• new or worsening breathing problems.Tell your doctor if you have shortness of breath or coughing with or without fever.
• high blood pressure.Your doctor should check your blood pressure before you start taking teriflunomide tablets and while you are taking teriflunomide tablets.

How Should I Store Teriflunomide Tablets? ⮝

• Store teriflunomide tablets at room temperature between 68 F to 77 F (20 C to 25 C).
• Keep teriflunomide tablets and all medicines out of reach of children.

General information about the safe and effective use of teriflunomide tablets.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use teriflunomide tablets for a condition for which it was not prescribed. Do not give teriflunomide tablets to other people, even if they have the same symptoms you have. It may harm them.
This Medication Guide summarizes the most important information about teriflunomide tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about teriflunomide tablets that is written for healthcare professionals.

Liver Problems: ⮝

Teriflunomide tablets may cause serious liver problems that may lead to death.Your risk of liver problems may be higher if you take other medicines that also affect your liver. Your doctor should do blood tests to check your liver:

within 6 months before you start taking teriflunomide tablets

1 time a month for 6 months after you start taking teriflunomide tablets

Call Your Doctor Right Away If You Have Any Of The Following Symptoms Of Liver Problems: ⮝

nausea

vomiting

stomach pain

loss of appetite

tiredness

your skin or the whites of your eyes turn yellow

dark urine

What Are Teriflunomide Tablets? ⮝

Teriflunomide tablets are a prescription medicine used to treat relapsing forms of multiple sclerosis (MS). Teriflunomide tablets can decrease the number of MS flare-ups (relapses). Teriflunomide tablets do not cure MS, but it can help slow down the physical problems that MS causes.

It is not known if teriflunomide tablets are safe and effective in children.

Do Not Take Teriflunomide Tablets If You: ⮝

you have had an allergic reaction to teriflunomide or a medicine called leflunomide

have severe liver problems

are pregnant or are of childbearing age and not using effective birth control

take a medicine called leflunomide

What Should I Tell My Doctor Before Taking Teriflunomide Tablets? ⮝

Before you take teriflunomide tablets, tell your doctor if you:

have liver or kidney problems

have a fever or infection, or you are unable to fight infections

have numbness or tingling in your hands or feet that is different from your MS symptoms

have diabetes

have had serious skin problems when taking other medicines

have breathing problems

have high blood pressure

are breastfeeding or plan to breastfeed. It is not known if teriflunomide passes into your breast milk. You and your doctor should decide if you will take teriflunomide tablets or breastfeed. You should not do both.

Tell your doctor about all the medicines you take,including prescription and non-prescription medicines, vitamins, and herbal supplements.Using teriflunomide tablets and other medicines may affect each other causing serious side effects. Teriflunomide tablets may affect the way other medicines work, and other medicines may affect how teriflunomide tablets work.

Especially tell your doctor if you take medicines that could raise your chance of getting infections, including medicines used to treat cancer or to control your immune system.

Ask your doctor or pharmacist for a list of these medicines if you are not sure.

Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.

How Should I Take Teriflunomide Tablets? ⮝

Take teriflunomide tablets exactly as your doctor tells you to take it.

Take teriflunomide tablets 1 time each day.

Take teriflunomide tablets with or without food.

Manufactured By: ⮝

Glenmark Pharmaceuticals Ltd.
Plot No. 2, Phase-2, Pharma Zone SEZ
Pithampur, Dist.- Dhar
Madhya Pradesh 454 775, India

Manufactured For: ⮝

Glenmark Pharmaceuticals Inc., USA
Mahwah, NJ 07430

Questions? 1(888)721-7115
www.glenmarkpharma.com/usa

November 2018

1. Highlights Of Prescribing Information
2. See Full Prescribing Information For Complete Boxed Warning.
4. Recent Major Changes
5. Indications And Usage
6. Dosage And Administration
7. Dosage Forms And Strengths
8. Contraindications
9. Warnings And Precautions
10. Adverse Reactions
11. Drug Interactions
12. Warning: Hepatotoxicity And Embryofetal Toxicity
13. 1 Indications And Usage
14. 2 Dosage And Administration
15. 3 Dosage Forms And Strengths
16. 4 Contraindications
17. 5 Warnings And Precautions
18. 6 Adverse Reactions
19. 7 Drug Interactions
20. 8 Use In Specific Populations
21. 10 Overdosage
22. 11 Description
23. 12 Clinical Pharmacology
24. 13 Nonclinical Toxicology
25. 14 Clinical Studies
26. 16 How Supplied/storage And Handling
27. Principal Display Panel
28. Warning: Hepatotoxicity And Risk Of Teratogenicity
29. 16 How Supplied/storage And Handling
30. Package/label Display Panel
31. See Full Prescribing Information For Complete Boxed Warning
32. Warning: Hepatotoxicity And Risk Of Teratogenicity
33. 1 Indications And Usage
34. 3 Dosage Forms And Strengths
35. 16 How Supplied/storage And Handling
36. Package Label.principal Display Panel

Highlights Of Prescribing Information ⮝

These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.

TERIFLUNOMIDE tablets, for oral use

Initial U.S. Approval: 2012

See Full Prescribing Information For Complete Boxed Warning. ⮝

• Hepatotoxicity
  Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide and monitor ALT levels at least monthly for six months (5.1). If drug induced liver injury is suspected, discontinue teriflunomide and start accelerated elimination procedure (5.3).

 ⮝

Embryofetal Toxicity
Teratogenicity and embryolethality occurred in animals administered teriflunomide (5.2, 8.1). Exclude pregnancy prior to initiating teriflunomide therapy (4, 5.2, 8.1, 8.3). Advise use of effective contraception in females of reproductive potential during treatment and during an accelerated drug elimination procedure (4, 5.2, 5.3, 8.1, 8.3). Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant (5.2, 5.3, 8.1).

Recent Major Changes ⮝

Boxed Warning, Risk of Teratogenicity 11/2016
Dosage and Administration (2) 11/2016
Contraindications, Hypersensitivity (4) 06/2016
Warnings and Precautions, Teratogenicity (5.2) 11/2016
Warnings and Precautions, Bone Marrow Effects/
Immunosuppression Potential/Infections (5.4) 06/2016
Warnings and Precautions, Hypersensitivity and
Serious Skin Reactions (5.5) 06/2016
Warnings and Precautions, Respiratory Effects (5.8) 06/2016

Indications And Usage ⮝

Teriflunomideis a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis (1)

Dosage And Administration ⮝

7 mg or 14 mg orally once daily, with or without food. (2)

Dosage Forms And Strengths ⮝

7 mg and 14 mg film-coated tablets (3)

Contraindications ⮝

• Severe hepatic impairment (4, 5.1)
• Pregnancy (4, 5.2, 8.1)
• Hypersensitivity (4, 5.5)
• Current leflunomide treatment (4)

Warnings And Precautions ⮝

• Elimination of teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days (5.3)
• Teriflunomide may decrease WBC. A recent CBC should be available before starting teriflunomide. Monitor for signs and symptoms of infection. Consider suspending treatment with teriflunomide in case of serious infection. Do not start teriflunomide in patients with active infections (5.4)
• Stop teriflunomide if patient has anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis; initiate rapid elimination (5.3, 5.5)
• If patient develops symptoms consistent with peripheral neuropathy, evaluate patient and consider discontinuing teriflunomide (5.6)
• Teriflunomide may increase blood pressure. Measure blood pressure at treatment initiation and monitor blood pressure during treatment (5.7)

Adverse Reactions ⮝

Most common adverse reactions ( 10% and 2% greater than placebo): headache, diarrhea, nausea, alopecia, increase in ALT (6)

To report SUSPECTED ADVERSE REACTIONS, contact MSN Pharmaceuticals Inc. at 1-848-200-1906 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions ⮝

• Drugs metabolized by CYP2C8 and OAT3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs (7)
• Teriflunomide may increase exposure of ethinylestradiol and levonorgestrel. Choose an appropriate oral contraceptive (7)
• Drugs metabolized by CYP1A2: Monitor patients because teriflunomide may decrease exposure of these drugs (7)
• Warfarin: Monitor INR as teriflunomide may decrease INR (7)
• Drugs metabolized by BCRP and OATP1B1/B3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs (7)
• Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking teriflunomide (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2019

Warning: Hepatotoxicity And Embryofetal Toxicity ⮝

• Hepatotoxicity

  Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury.
  Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide [see Warnings and Precautions (5.1)]. If drug induced liver injury is suspected, discontinue teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3)]. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4)]. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide.

• Embryofetal Toxicity
  Teriflunomide is contraindicated for use in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposures lower than that in humans. Exclude pregnancy before the start of treatment with teriflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during teriflunomide treatment and during an accelerated drug elimination procedure after teriflunomide treatment. Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant [see Contraindications (4), Warnings and Precautions (5.2, 5.3), Use in Specific Populations (8.1, 8.3), and Clinical Pharmacology (12.3)].

1 Indications And Usage ⮝

Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis.

2 Dosage And Administration ⮝

The recommended dose of teriflunomide tablet is 7 mg or 14 mg orally once daily. Teriflunomide tablet can be taken with or without food.

Monitoring to assess safety

• Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide tablet therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide tablets[see Warnings and Precautions (5.1)].
• Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with teriflunomide tablets. Further monitoring should be based on signs and symptoms of infection [see Warnings and Precautions (5.4)].
• Prior to initiating teriflunomide tablets, screen patients for latent tuberculosis infection with a tuberculin skin test or blood test for mycobacterium tuberculosis infection [see Warnings and Precautions (5.4)].
• Exclude pregnancy prior to initiation of treatment with teriflunomide tablets in females of reproductive potential [see Warnings and Precautions (5.2)].
• Check blood pressure before start of teriflunomide tablets treatment and periodically thereafter [see Warnings and Precautions (5.7)].

3 Dosage Forms And Strengths ⮝

Teriflunomide is available as 7 mg and 14 mg tablets.

The 14 mg tablet is a light blue to blue, biconvex, round film-coated tablet debossed with G on one side and 42 on the other side. Each tablet contains 14 mg of teriflunomide.

The 7 mg tablet is a light green to green, biconvex, round film-coated tablet debossed with G on one side and 43 on the other side. Each tablet contains 7 mg of teriflunomide.

4 Contraindications ⮝

Teriflunomide is contraindicated in/with:

• Patients with severe hepatic impairment [see Warnings and Precautions (5.1)].
• Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide may cause fetal harm [see Warnings and Precautions (5.2 and 5.3) and Use in Specific Populations (8.1)].
• Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide. Reactions have included anaphylaxis, angioedema, and serious skin reactions[see Warnings and Precautions (5.5)].
• Coadministration with leflunomide [see Clinical Pharmacology (12.3)].

5 Warnings And Precautions ⮝

5.1 Hepatotoxicity

Severe liver injury including fatal liver failure and dysfunction has been reported in some patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide. Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than two times the upper limit of normal (ULN) before initiating treatment, should not normally be treated with teriflunomide. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4)].

In placebo-controlled trials, ALT greater than three times the ULN occurred in 61/1045 (5.8%) and 62/1002 (6.2%) of patients receiving teriflunomide 7 mg and 14 mg, respectively, and 38/997 (3.8%) of patients receiving placebo, during the treatment period. These elevations occurred mostly within the first year of treatment. Half of the cases returned to normal without drug discontinuation. In clinical trials, if ALT elevation was greater than three times the ULN on two consecutive tests, teriflunomide was discontinued and patients underwent an accelerated elimination procedure [see Warnings and Precautions (5.3)]. Of the patients who underwent discontinuation and accelerated elimination in controlled trials, half returned to normal or near normal values within 2 months.

One patient in the controlled trials developed ALT 32 times the ULN and jaundice 5 months after initiation of teriflunomide 14 mg treatment. The patient was hospitalized for 5 weeks and recovered after plasmapheresis and cholestyramine accelerated elimination procedure.

Teriflunomide-induced liver injury in this patient could not be ruled out.

Obtain serum transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide. Consider additional monitoring when teriflunomide is given with other potentially hepatotoxic drugs.

Consider discontinuing teriflunomide if serum transaminase increase (greater than three times the ULN) is confirmed. Monitor serum transaminase and bilirubin on teriflunomide therapy, particularly in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. If liver injury is suspected to be teriflunomide -induced, discontinue teriflunomide and start an accelerated elimination procedure [see Warnings and Precautions (5.3)] and monitor liver tests weekly until normalized. If teriflunomide-induced liver injury is unlikely because some other probable cause has been found, resumption of teriflunomide therapy may be considered.

5.2 Teratogenicity

Teriflunomide may cause fetal harm when administered to a pregnant woman. Teratogenicity and embryo-fetal lethality occurred in animal reproduction studies in multiple animal species at plasma teriflunomide exposures similar to or lower than that in humans at the maximum human recommended dose (MHRD) of 14 mg/day [see Use in Specific Populations (8.1) ] .
Teriflunomide is contraindicated for use in pregnant women and females of reproductive potential not using effective contraception [see Contraindications (4)and Warnings and Precautions (5.3)] .

5.3 Procedure for Accelerated Elimination of Teriflunomide

Teriflunomide is eliminated slowly from the plasma [see Clinical Pharmacology (12.3)]. Without an accelerated elimination procedure, it takes on average 8 months to reach plasma concentrations less than 0.02 mg/L, although because of individual variations in drug clearance it may take as long as 2 years. An accelerated elimination procedure could be used at any time after discontinuation of teriflunomide. Elimination can be accelerated by either of the following procedures:

• Administration of cholestyramine 8 g every 8 hours for 11 days. If cholestyramine 8 g three times a day is not well tolerated, cholestyramine 4 g three times a day can be used.
• Administration of 50 g oral activated charcoal powder every 12 hours for 11 days.

If either elimination procedure is poorly tolerated, treatment days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly.

At the end of 11 days, both regimens successfully accelerated teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations.

Use of the accelerated elimination procedure may potentially result in return of disease activity if the patient had been responding to teriflunomide treatment.

5.4 Bone Marrow Effects/Immunosuppression Potential/Infections

Bone Marrow Effects

A mean decrease compared to baseline in white blood cell (WBC) count of approximately 15% (mainly neutrophils and lymphocytes) and in platelet count of approximately 10% was observed in placebo- controlled trials with 7 mg and 14 mg of teriflunomide. The decrease in mean WBC count occurred during the first 6 weeks and WBC count remained low during treatment. In placebo-controlled studies, neutrophil count < 1.5x109/L was observed in 12% and 16% of patients receiving teriflunomide 7 mg and 14 mg, respectively, compared with 7% of patients receiving placebo; lymphocyte count <0.8x109/L was observed in 10% and 12% of patients receiving teriflunomide 7 mg and 14 mg, respectively, compared with 6% of patients receiving placebo. No cases of serious pancytopenia were reported in premarketing clinical trials of teriflunomide but rare cases of pancytopenia and agranulocytosis have been reported in the postmarketing setting with leflunomide. A similar risk would be expected for teriflunomide [see Clinical Pharmacology (12.3)]. Cases of thrombocytopenia with teriflunomide, including rare cases with platelet counts less than 50,000/mm3, have been reported in the postmarketing setting. Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with teriflunomide. Further monitoring should be based on signs and symptoms suggestive of bone marrow suppression.

Risk of Infection/Tuberculosis Screening

Patients with active acute or chronic infections should not start treatment until the infection(s) is resolved. If a patient develops a serious infection consider suspending treatment with teriflunomide and using an accelerated elimination procedure. Reassess the benefits and risks prior to resumption of therapy. Instruct patients receiving teriflunomide to report symptoms of infections to a physician.

Teriflunomide is not recommended for patients with severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections. Medications like teriflunomide that have immunosuppression potential may cause patients to be more susceptible to infections, including opportunistic infections.

In placebo-controlled studies of teriflunomide, no overall increase in the risk of serious infections was observed with teriflunomide 7 mg (2.2%) or 14 mg (2.7%) compared to placebo (2.2%).

However, one fatal case of klebsiella pneumonia sepsis occurred in a patient taking teriflunomide 14 mg for 1.7 years. Fatal infections have been reported in the post-marketing setting in patients receiving leflunomide, especially Pneumocystis jiroveci pneumonia and aspergillosis. Most of the reports were confounded by concomitant immunosuppressant therapy and/or comorbid illness which, in addition to rheumatoid disease, may predispose patients to infection. In clinical studies with teriflunomide, cytomegalovirus hepatitis reactivation has been observed.

In clinical studies with teriflunomide, cases of tuberculosis have been observed. Prior to initiating teriflunomide, screen patients for latent tuberculosis infection with a tuberculin skin test or with a blood test for mycobacterium tuberculosis infection. Teriflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of teriflunomide in individuals with latent tuberculosis infection is unknown. For patients testing positive in tuberculosis screening, treat by standard medical practice prior to therapy with teriflunomide.

Vaccination

No clinical data are available on the efficacy and safety of live vaccinations in patients taking teriflunomide. Vaccination with live vaccines is not recommended. The long half-life of teriflunomide should be considered when contemplating administration of a live vaccine after stopping teriflunomide.

Malignancy

The risk of malignancy, particularly lymphoproliferative disorders, is increased with the use of some immunosuppressive medications. There is a potential for immunosuppression with teriflunomide. No apparent increase in the incidence of malignancies and lymphoproliferative disorders was reported in the teriflunomide clinical trials, but larger and longer-term studies would be needed to determine whether there is an increased risk of malignancy or lymphoproliferative disorders with teriflunomide.

5.5 Hypersensitivity and Serious Skin Reactions

Teriflunomide can cause anaphylaxis and severe allergic reactions [see Contraindications (4)]. Signs and symptoms have included dyspnea, urticaria, and angioedema including lips, eyes, throat, and tongue.

Cases of serious skin reactions, including cases of Stevens-Johnson syndrome (SJS) and a fatal case of toxic epidermal necrolysis (TEN), have been reported with teriflunomide.

In patients treated with leflunomide, the parent compound, very rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.

Inform patients of the signs and symptoms of anaphylaxis and angioedema and signs and symptoms that may signal a serious skin reaction. Inform patients that a fever associated with signs of other organ system involvement (e.g., rash, lymphadenopathy, or hepatic dysfunction) may be drug-related. Instruct patients to discontinue teriflunomide and seek immediate medical care should these signs and symptoms occur. Discontinue teriflunomide, unless the reactions are clearly not drug-related, and begin an accelerated elimination procedure immediately [see Warnings and Precautions (5.3)]. In such cases, patients should not be re-exposed to teriflunomide [see Contraindications (4)].

5.6 Peripheral Neuropathy

In placebo-controlled studies, peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), occurred more frequently in patients taking teriflunomide than in patients taking placebo. The incidence of peripheral neuropathy confirmed by nerve conduction studies was 1.4% (13 patients) and 1.9% (17 patients) of patients receiving 7 mg and 14 mg of teriflunomide, respectively, compared with 0.4% receiving placebo (4 patients). Treatment was discontinued in 0.7% (8 patients) with confirmed peripheral neuropathy (3 patients receiving teriflunomide 7 mg and 5 patients receiving teriflunomide 14 mg). Five of them recovered following treatment discontinuation. Not all cases of peripheral neuropathy resolved with continued treatment. Peripheral neuropathy also occurred in patients receiving leflunomide

Age older than 60 years, concomitant neurotoxic medications, and diabetes may increase the risk for peripheral neuropathy. If a patient taking teriflunomide develops symptoms consistent with peripheral neuropathy, such as bilateral numbness or tingling of hands or feet, consider discontinuing teriflunomide therapy and performing an accelerated elimination procedure [see Warnings and Precautions (5.3)].

5.7 Increased Blood Pressure

In placebo-controlled studies, the mean change from baseline to the end of study in systolic blood pressure was +2.3 mmHg and +2.7 mmHg for teriflunomide 7 mg and 14 mg, respectively, and -0.6 mmHg for placebo. The change from baseline in diastolic blood pressure was +1.4 mmHg and +1.9 mmHg for teriflunomide 7 mg and 14 mg, respectively, and -0.3 mmHg for placebo. Hypertension was an adverse reaction in 3.1% and 4.3% of patients treated with 7 mg or 14 mg of teriflunomide compared with 1.8% for placebo. Check blood pressure before start of teriflunomide treatment and periodically thereafter. Elevated blood pressure should be appropriately managed during treatment with teriflunomide.

5.8 Respiratory Effects

Interstitial lung disease, including acute interstitial pneumonitis, has been reported with teriflunomide in the postmarketing setting.

Interstitial lung disease and worsening of pre-existing interstitial lung disease have been reported during treatment with leflunomide. Interstitial lung disease may be fatal and may occur acutely at any time during therapy with a variable clinical presentation. New onset or worsening pulmonary symptoms, such as cough and dyspnea, with or without associated fever, may be a reason for discontinuation of therapy and for further investigation as appropriate. If discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure [see Warnings and Precautions (5.3)].

5.9 Concomitant Use with Immunosuppressive or Immunomodulating Therapies

Co-administration with antineoplastic, or immunosuppressive therapies used for treatment of multiple sclerosis has not been evaluated. Safety studies in which teriflunomide was concomitantly administered with other immune modulating therapies for up to one year (interferon beta, glatiramer acetate) did not reveal any specific safety concerns. The long term safety of these combinations in the treatment of multiple sclerosis has not been established.

In any situation in which the decision is made to switch from teriflunomide to another agent with a known potential for hematologic suppression, it would be prudent to monitor for hematologic toxicity, because there will be overlap of systemic exposure to both compounds. Use of an accelerated elimination procedure may decrease this risk, but may also potentially result in return of disease activity if the patient had been responding to teriflunomide treatment [see Warnings and Precautions (5.3)].

6 Adverse Reactions ⮝

The following serious adverse reactions are described elsewhere in the prescribing information:

• Hepatotoxicity [see Contraindications (4) and Warnings and Precautions (5.1)]
• Bone Marrow Effects /Immunosuppression Potential/Infections [see Warnings and Precautions (5.4)]
• Hypersensitivity and Serious Skin Reactions [see Contraindications (4) and Warnings and Precautions (5.5)]
• Peripheral Neuropathy [see Warnings and Precautions (5.6)]
• Increased Blood Pressure [see Warnings and Precautions (5.7)]
• Respiratory Effects [see Warnings and Precautions (5.8)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 2047 patients receiving teriflunomide (7 mg or 14 mg once daily) constituted the safety population in the pooled analysis of placebo controlled studies in patients with relapsing forms of multiple sclerosis; of these, 71% were female. The average age was 37 years.
Table 1 lists adverse reactions in placebo-controlled trials with rates that were at least 2% for teriflunomide patients and also at least 2% above the rate in placebo patients. The most common were headache, an increase in ALT, diarrhea, alopecia, and nausea. The adverse reaction most commonly associated with discontinuation was an increase in ALT (3.3%, 2.6%, and 2.3% of all patients in the teriflunomide 7 mg, teriflunomide 14 mg, and placebo treatment arms, respectively).

Table 1. Adverse Reactions in Pooled Placebo-Controlled Studies in Patients with Relapsing Forms of Multiple Sclerosis

Adverse Reaction	Teriflunomide 7 mg (N=1045)	Teriflunomide 14 mg (N=1002)	Placebo (N=997)
Headache	18%	16%	15%
Increase in Alanine aminotransferase	13%	15%	9%
Diarrhea	13%	14%	8%
Alopecia	10%	13%	5%
Nausea	8%	11%	7%
Paresthesia	8%	9%	7%
Arthralgia	8%	6%	5%
Neutropenia	4%	6%	2%
Hypertension	3%	4%	2%

Cardiovascular deaths

Four cardiovascular deaths, including three sudden deaths, and one myocardial infarction in a patient with a history of hyperlipidemia and hypertension were reported among approximately 2600 patients exposed to teriflunomide in the premarketing database. These cardiovascular deaths occurred during uncontrolled extension studies, one to nine years after initiation of treatment. A relationship between teriflunomide and cardiovascular death has not been established.

Acute Renal Failure

In placebo-controlled studies, creatinine values increased more than 100% over baseline in 8/1045 (0.8%) patients in the 7 mg teriflunomide group and 6/1002 (0.6%) patients in the 14 mg teriflunomide group versus 4/997 (0.4%) patients in the placebo group. These elevations were transient. Some elevations were accompanied by hyperkalemia. Teriflunomide may cause acute uric acid nephropathy with transient acute renal failure because teriflunomide increases renal uric acid clearance.

Hypophosphatemia

In clinical trials, 18% of teriflunomide -treated patients had hypophosphatemia with serum phosphorus levels of at least 0.6 mmol/L, compared to 7% of placebo-treated patients; 4% of teriflunomide -treated patients had hypophosphatemia with serum phosphorus levels at least 0.3 mmol/L but less than 0.6 mmol/L, compared to 0.8% of placebo-treated patients. No patient in any treatment group had a serum phosphorus below 0.3 mmol/L.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of teriflunomide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

• Hypersensitivity reactions, some of which were severe, such as anaphylaxis and angioedema [see Warnings and Precautions (5.5)]
• Severe skin reactions, including toxic epidermal necrolysis and Stevens-Johnson syndrome [see Warnings and Precautions (5.5)]
• Thrombocytopenia [see Warnings and Precautions (5.4)]
• Interstitial lung disease [see Warnings and Precautions (5.8)]
• Pancreatitis

7 Drug Interactions ⮝

Effect of teriflunomide on CYP2C8 substrates

Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking teriflunomide, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].

Effect of teriflunomide on warfarin

Coadministration of teriflunomide with warfarin requires close monitoring of the international normalized ratio (INR) because teriflunomide may decrease peak INR by approximately 25%.

Effect of teriflunomide on oral contraceptives

Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with teriflunomide [see Clinical Pharmacology (12.3)].

Effect of teriflunomide on CYP1A2 substrates

Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking teriflunomide, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].

Effect of teriflunomide on organic anion transporter 3 (OAT3) substrates

Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking teriflunomide, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].

Effect of teriflunomide on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates

Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking teriflunomide, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking teriflunomide [see Clinical Pharmacology (12.3)].

8 Use In Specific Populations ⮝

8.1 Pregnancy

Risk Summary
Teriflunomide is contraindicated for use in pregnant women and females of reproductive potential not using effective contraception because of the potential for fetal harm based on animal data. Human data are not available at this time to inform the presence or absence of drug-associated risk with the use of teriflunomide during pregnancy.
In animal reproduction studies in rat and rabbits, oral administration of teriflunomide during organogenesis caused teratogenicity and embryolethality at plasma exposures (AUC) lower than that at the maximum human recommended dose (MHRD) of 14 mg/day [see Data].
In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage in the indicated population is unknown.

Clinical Considerations
Women who wish to become pregnant should discontinue use of teriflunomide and undergo an accelerated elimination procedure to decrease the plasma concentration of teriflunomide to less than 0.02 mg/L (0.02 mcg/mL). Effective contraception should be used until is it verified that plasma concentrations of teriflunomide are less than 0.02 mg/L (0.02 mcg/mL) [see Warnings and Precautions (5.3) ]. Human plasma concentrations of teriflunomide less than 0.02 mg/L (0.02 mcg/mL) are expected to have minimal embryofetal risk [see Contraindications (4)and Warnings and Precautions (5.3) ].
If the patient becomes pregnant while taking this drug, stop treatment with teriflunomide, inform the patient of the potential risk to the fetus, and perform the accelerated drug elimination procedure to achieve plasma concentrations of less than 0.02 mg/L (0.02 mcg/mL) [see Warnings and Precautions (5.3)and Clinical Pharmacology (12.3) ]. Refer the patient to an obstetrician/gynecologist, preferably experienced in reproductive toxicity, for further evaluation and counseling [see Warnings and Precautions (5.2,5.3) ].
Data
Animal Data
When teriflunomide (oral doses of 1, 3, or 10 mg/kg/day) was administered to pregnant rats throughout the period of organogenesis, high incidences of fetal malformation (primarily craniofacial, and axial and appendicular skeletal defects) and embryofetal death were observed at doses not associated with maternal toxicity. Adverse effects on embryofetal development were observed following dosing at various stages throughout organogenesis. Maternal plasma exposure at the no-effect level (1 mg/kg/day) for embryofetal developmental toxicity in rats was less than that in humans at the maximum recommended human dose (MRHD, 14 mg/day).
Administration of teriflunomide (oral doses of 1, 3.5, or 12 mg/kg/day) to pregnant rabbits throughout organogenesis resulted in high incidences of fetal malformation (primarily craniofacial, and axial and appendicular skeletal defects) and embryofetal death at doses associated with minimal maternal toxicity. Maternal plasma exposure at the no-effect dose (1 mg/kg/day) for embryofetal developmental toxicity in rabbits was less than that in humans at the MRHD.
In studies in which teriflunomide (oral doses of 0.05, 0.1, 0.3, 0.6, or 1.0 mg/kg/day) was administered to rats during gestation and lactation, decreased growth, eye and skin abnormalities, and high incidences of malformation (limb defects) and postnatal death were observed in the offspring at doses not associated with maternal toxicity. Maternal plasma exposure at the no- effect dose for pre- and postnatal developmental toxicity in rats (0.10 mg/kg/day) was less than that in humans at the MRHD.
In animal reproduction studies of leflunomide, embryolethality and teratogenic effects were observed in pregnant rat and rabbit at or below clinically relevant plasma teriflunomide exposures (AUC). In published reproduction studies in pregnant mice, leflunomide was embryolethal and increased the incidence of malformations (craniofacial, axial skeletal, heart and great vessel). Supplementation with exogenous uridine reduced the teratogenic effects in pregnant mice, suggesting that the mode of action (inhibition of mitochondrial enzyme dihydroorotate dehydrogenase) is the same for therapeutic efficacy and developmental toxicity.
At recommended doses in humans, teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.

8.2 Lactation

Risk Summary
It is not known whether this drug is excreted in human milk. Teriflunomide was detected in rat milk following a single oral dose.
The developmental and health benefits of breastfeeding should be considered along with the mother s clinical need for teriflunomide and any potential adverse effects on the breastfed infant from teriflunomide or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing
Exclude pregnancy prior to initiation of treatment with teriflunomide in females of reproductive potential. Advise females to notify their healthcare provider immediately if pregnancy occurs or is suspected during treatment [see Warnings and Precautions (5.2,5.3) and Use in Specific Populations (8.1)].
Contraception
Females
Females of reproductive potential should use effective contraception while taking teriflunomide. If teriflunomide is discontinued, use of contraception should be continued until is it verified that plasma concentrations of teriflunomide are less than 0.02 mg/L (0.02 mcg/mL).
Females of reproductive potential who wish to become pregnant should undergo an accelerated elimination procedure. Effective contraception should be used until it is verified that plasma concentrations of teriflunomide are less than 0.02 mg/L (0.02 mcg/mL) [see Warnings and Precautions (5.3) ].
Males
Teriflunomide is detected in human semen. Animal studies to specifically evaluate the risk of male- mediated fetal toxicity have not been conducted. To minimize any possible risk, men not wishing to father a child and their female partners should use effective contraception. Men wishing to father a child should discontinue use of teriflunomide and either undergo an accelerated elimination procedure or wait until verification that the plasma teriflunomide concentration is less than 0.02 mg/L (0.02 mcg/mL) [see Warnings and Precautions (5.3)].
Infertility
Administration of teriflunomide to male rats resulted in no adverse effects on fertility. However, reduced epididymal sperm count was observed [see Nonclinical Toxicology (13.1)]. Effects of teriflunomide on fertility in humans have not been evaluated.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies of teriflunomide did not include patients over 65 years old.

8.6 Hepatic Impairment

No dosage adjustment is necessary for patients with mild and moderate hepatic impairment. The pharmacokinetics of teriflunomide in severe hepatic impairment have not been evaluated. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].

8.7 Renal Impairment

No dosage adjustment is necessary for patients with mild, moderate, and severe renal impairment [see Clinical Pharmacology (12.3)].

10 Overdosage ⮝

There is no experience regarding teriflunomide overdose or intoxication in humans. Teriflunomide 70 mg daily up to 14 days was well tolerated by healthy subjects.

In the event of clinically significant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination [see Warnings and Precautions (5.3)].

11 Description ⮝

Teriflunomide is an oral de novo pyrimidine synthesis inhibitor of the DHO-DH enzyme, with the chemical name (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-trifluoro methyl phenyl)-amide. Its molecular weight is 270.21, and the structural formula is C12H9F3N2O2 with the following chemical structure:

Teriflunomide is a white to almost white powder that is soluble in N, N-Dimethyl formamide, sparingly soluble in acetone and insoluble in water.

Teriflunomide is formulated as film-coated tablets for oral administration. Teriflunomide tablets contain 7 mg or 14 mg of teriflunomide and the following inactive ingredients: colloidal silicon dioxide, corn starch, hydroxy propyl cellulose, lactose monohydrate, magnesium stearate and sodium starch glycolate. The film coating for the 14 mg tablet is made of hypromellose, titanium dioxide, polyethylene glycol indigo carmine aluminum lake and iron oxide yellow. In addition to these, the 7 mg tablet film coating includes talc and brilliant blue aluminum lake.

12 Clinical Pharmacology ⮝

12.1 Mechanism of Action

Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of activated lymphocytes in CNS.

12.2 Pharmacodynamics

Potential to prolong the QT interval

In a placebo controlled thorough QT study performed in healthy subjects, there was no evidence that teriflunomide caused QT interval prolongation of clinical significance (i.e., the upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 ms).

12.3 Pharmacokinetics

Teriflunomide is the principal active metabolite of leflunomide and is responsible for leflunomide s activity in vivo. At recommended doses, teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.

Based on a population analysis of teriflunomide in healthy volunteers and MS patients, median t1/2 was approximately 18 and 19 days after repeated doses of 7 mg and 14 mg respectively. It takes approximately 3 months respectively to reach steady-state concentrations. The estimated AUC accumulation ratio is approximately 30 after repeated doses of 7 or 14 mg.

Absorption

Median time to reach maximum plasma concentrations is between 1 to 4 hours post dose following oral administration of teriflunomide.
Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.
Distribution

Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma. The volume of distribution is 11 L after a single intravenous (IV) administration.
Metabolism

Teriflunomide is the major circulating moiety detected in plasma. The primary biotransformation pathway to minor metabolites of teriflunomide is hydrolysis, with oxidation being a minor pathway. Secondary pathways involve oxidation, N-acetylation and sulfate conjugation.
Elimination

Teriflunomide is eliminated mainly through direct biliary excretion of unchanged drug as well as renal excretion of metabolites. Over 21 days, 60.1% of the administered dose is excreted via feces (37.5%) and urine (22.6%). After an accelerated elimination procedure with cholestyramine, an additional 23.1% was recovered (mostly in feces). After a single IV administration, the total body clearance of teriflunomide is 30.5 mL/h.
Drug Interaction Studies

Teriflunomide is not metabolized by Cytochrome P450 or flavin monoamine oxidase enzymes.

The Potential Effect of teriflunomide on Other Drugs

• CYP2C8 Substrates

There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose [see Drug Interactions (7) ].

• CYP1A2 Substrates

Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo [see Drug Interactions (7)].

• OAT3 Substrates

There was an increase in mean cefaclor Cmaxand AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo [see Drug Interactions (7)].

• BCRP and OATP1B1/1B3 Substrates

There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) [see Drug Interactions (7)].

• Oral Contraceptives

There was an increase in mean ethinylestradiol Cmaxand AUC0-24(1.58- and 1.54-fold, respectively) and levonorgestrel Cmaxand AUC0-24(1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].

• Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).

The Potential Effect of Other Drugs on teriflunomide

• Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.

Specific populations

• Hepatic Impairment

Mild and moderate hepatic impairment had no impact on the pharmacokinetics of teriflunomide. The pharmacokinetics of teriflunomide in severe hepatic impairment have not been evaluated [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.6)].

• Renal Impairment

Severe renal impairment had no impact on the pharmacokinetics of teriflunomide [see Use in Specific Populations (8.7)].

• Gender

In a population analysis, the clearance rate for teriflunomide is 23% less in females than in males.

• Race

Effect of race on the pharmacokinetics of teriflunomide cannot be adequately assessed due to a low number of non-white patients in the clinical trials.

13 Nonclinical Toxicology ⮝

13.1 Carcinogenesis, Mutagenesis , Impairment of Fertility

Carcinogenesis

No evidence of carcinogenicity was observed in lifetime carcinogenicity bioassays in mouse and rat. In mouse, teriflunomide was administered orally at doses up to 12 mg/kg/day for up to 95 -104 weeks; plasma teriflunomide exposures (AUC) at the highest dose tested are approximately 3 times that in humans at the maximum recommended human dose (MRHD, 14 mg/day). In rat, teriflunomide was administered orally at doses up to 4 mg/kg/day for up to 97-104 weeks; plasma teriflunomide AUCs at the highest doses tested are less than that in humans at the MRHD.

Mutagenesis

Teriflunomide was negative in the in vitro bacterial reverse mutation (Ames) assay, the in vitro HPRT assay, and in in vivo micronucleus and chromosomal aberration assays. Teriflunomide was positive in an in vitro chromosomal aberration assay in human lymphocytes, with and without metabolic activation. Addition of uridine (to supplement the pyrimidine pool) reduced the magnitude of the clastogenic effect; however, teriflunomide was positive in the in vitro chromosomal aberration assay, even in the presence of uridine.

4-Trifluoromethylaniline (4-TFMA), a minor metabolite of teriflunomide, was positive in the in vitro bacterial reverse mutation (Ames) assay, the in vitro HPRT assay, and the in vitro chromosomal aberration assay in mammalian cells. 4-TFMA was negative in in vivo micronucleus and chromosomal aberration assays.

Impairment of fertility

Oral administration of teriflunomide (0, 1, 3, 10 mg/kg/day) to male rats prior to and during mating (to untreated females) resulted in no adverse effects on fertility; however, reduced epididymal sperm count was observed at the mid and high doses tested. The no-effect dose for reproductive toxicity in male rats (1 mg/kg) is less than the MRHD on a mg/m2 basis.

Oral administration of teriflunomide (0, 0.84, 2.6, 8.6 mg/kg/day) to female rats, prior to and during mating (to untreated males) and continuing to gestation day 6, resulted in embryolethality, reduced fetal body weight, and/or malformations at all doses tested. Due to marked embryolethality at the highest dose tested, no fetuses were available for evaluation. The lowest dose tested is less than the MRHD on a mg/m2 basis.

14 Clinical Studies ⮝

Four randomized, controlled, double-blind clinical trials established the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.

Study 1 was a double-blind, placebo-controlled clinical trial that evaluated once daily doses of teriflunomide 7 mg and teriflunomide 14 mg for up to 26 months in patients with relapsing forms of multiple sclerosis. Patients were required to have a diagnosis of multiple sclerosis exhibiting a relapsing clinical course, with or without progression, and to have experienced at least one relapse over the year preceding the trial or at least two relapses over the two years preceding the trial. Patients were required not to have received interferon-beta for at least four months, or any other multiple sclerosis medication for at least six months before entering the study, nor were these medications permitted during the study. Neurological evaluations were to be performed at screening, every 12 weeks until week 108, and after suspected relapses. MRI was to be performed at screening, and at Week 24, 48, 72, and 108. The primary endpoint was the annualized relapse rate (ARR).

In Study 1, 1088 patients were randomized to receive teriflunomide 7 mg (n=366), teriflunomide 14 mg (n=359), or placebo (n=363). At entry, patients had an Expanded Disability Status Scale (EDSS) score 5.5. Patients had a mean age of 38 years, mean disease duration of 5 years, and mean EDSS at baseline of 2.7. A total of 91% of patients had relapsing remitting multiple sclerosis, and 9% had a progressive form of multiple sclerosis with relapses. The mean duration of treatment was 635, 627, and 631 days for teriflunomide 7 mg, teriflunomide 14 mg, and placebo, respectively. The percentage of patients who completed the study treatment period was 75%, 73%, and 71% for teriflunomide 7 mg, teriflunomide 14 mg, and placebo, respectively.

There was a statistically significant reduction in ARR for patients who received teriflunomide 7 mg or teriflunomide 14 mg, compared to patients who received placebo (see Table 2). There was a consistent reduction of the ARR noted in subgroups defined by sex, age group, prior multiple sclerosis therapy, and baseline disease activity.

There was a statistically significant reduction in the relative risk of disability progression at week 108 sustained for 12 weeks (as measured by at least a 1-point increase from baseline EDSS 5.5 or a 0.5 point increase for those with a baseline EDSS > 5.5) in the teriflunomide 14 mg group compared to placebo (see Table 2 and Figure 1).

The effect of teriflunomide on several magnetic resonance imaging (MRI) variables including the total lesion volume of T2 and hypointense T1 lesions, was assessed in Study 1. The change in total lesion volume from baseline was significantly lower in the teriflunomide 7 mg and teriflunomide 14 mg groups than in the placebo group. Patients in both teriflunomide groups had significantly fewer gadolinium-enhancing lesions per T1-weighted scan than those in the placebo group (see Table 2).

Table 2. Clinical and MRI Results of Study 1

	Teriflunomide 7 mg N=365	Teriflunomide 14 mg N=358	Placebo N=363
Clinical Endpoints
Annualized relapse rate	0.370 (p=0.0002)	0.369 (p=0.0005)	0.539
Relative risk reduction	31%	31%
Percent of patients remaining relapse-free at week 108	53.7%	56.5%	45.6%
Percent disability progression at week 108	21.7% (p=0.084)	20.2% (p=0.028)	27.3%
Hazard ratio	0.76	0.70
MRI Endpoints
Median change from baseline in Total lesion volume1 (mL) at week 108	0.755 (p=0.0317)2	0.345 (p=0.0003)2	1.127
Mean number of Gd-enhancing T1-lesions per scan	0.570 (p<0.0001)	0.261 (p<0.0001)	1.331

1Total lesion volume: sum of T2 and hypointense T1 lesion volume in mL

2p-values based on cubic root transformed data for total lesion volume

Figure 1. Kaplan-Meier plot of time to disability progression sustained for 12 weeks (Study 1)

Study 2 was a double-blind, placebo-controlled clinical trial that evaluated once daily doses of teriflunomide 7 mg and teriflunomide 14 mg for up to 40 months in patients with relapsing forms of multiple sclerosis. Patients were required to have a diagnosis of multiple sclerosis exhibiting a relapsing clinical course and to have experienced at least one relapse over the year preceding the trial, or at least two relapses over the two years preceding the trial. Patients were required not to have received any multiple sclerosis medication for at least three months before entering the trial, nor were these medications permitted during the trial. Neurological evaluations were to be performed at screening, every 12 weeks until completion, and after every suspected relapse. The primary end point was the ARR.

A total of 1165 patients received teriflunomide 7 mg (n=407), teriflunomide 14 mg (n=370), or placebo (n=388). Patients had a mean age of 38 years, a mean disease duration of 5 years, and a mean EDSS at baseline of 2.7. A total of 98% of patients had relapsing remitting multiple sclerosis, and 2% had a progressive form of multiple sclerosis with relapses. The mean duration of treatment was 552, 567, and 571 days for teriflunomide 7 mg, teriflunomide 14 mg, and placebo, respectively. The percentage of patients who completed the study treatment period was 67%, 66%, and 68% for teriflunomide 7 mg, teriflunomide 14 mg, and placebo, respectively.

There was a statistically significant reduction in the ARR for patients who received teriflunomide 7 mg or teriflunomide 14 mg compared to patients who received placebo (see Table 3). There was a consistent reduction of the ARR noted in subgroups defined by sex, age group, prior multiple sclerosis therapy, and baseline disease activity.

There was a statistically significant reduction in the relative risk of disability progression at week 108 sustained for 12 weeks (as measured by at least a 1-point increase from baseline EDSS 5.5 or a 0.5 point increase for those with a baseline EDSS > 5.5) in the teriflunomide 14 mg group compared to placebo (See Table 3 and Figure 2).

Table 3. Clinical Results of Study 2

	Teriflunomide 7 mg N=407	Teriflunomide 14 mg N=370	Placebo N=388
Clinical Endpoints
Annualized relapse rate	0.389 (p = 0.0183)	0.319 (p = 0.0001)	0.501
Relative risk reduction	22%	36%
Percent of patients remaining relapse-free at week 108	58.2%	57.1%	46.8%
Percent disability progression at week 108	21.1% (p = 0.762)	15.8% (p = 0.044)	19.7%
Hazard ratio	0.96	0.69

Figure 2. Kaplan-Meier plot of time to disability progression sustained for 12 weeks (Study 2)

Study 3 was a double-blind, placebo-controlled clinical trial that evaluated once daily doses of teriflunomide 7 mg and teriflunomide 14 mg for up to 108 weeks in patients with relapsing multiple sclerosis. Patients were required to have had a first clinical event consistent with acute demyelination occurring within 90 days of randomization with 2 or more T2 lesions at least 3 mm in diameter that were characteristic of multiple sclerosis. A total of 614 patients received teriflunomide 7 mg (n=203), teriflunomide 14 mg (n=214), or placebo (n=197). Patients had a mean age of 32 years, EDSS at baseline of 1.7, and mean disease duration of two months. The proportion of patients free of relapse was greater in the teriflunomide 7 mg (70.5%, p < 0.05) and teriflunomide 14 mg (72.2%, p < 0.05) groups than in the placebo group (61.7%).

The effect of teriflunomide on MRI activity was also demonstrated in Study 4, a randomized, double-blind, placebo-controlled clinical trial of multiple sclerosis patients with relapse. In Study 4, MRI was to be performed at baseline, 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, and 36 weeks after treatment initiation. A total of 179 patients were randomized to teriflunomide 7 mg (n=61), teriflunomide 14 mg (n=57), or placebo (n= 61). Baseline demographics were consistent across treatment groups. The primary endpoint was the average number of unique active lesions/MRI scan during treatment. The mean number of unique active lesions per brain MRI scan during the 36-week treatment period was lower in patients treated with teriflunomide 7 mg (1.06) and teriflunomide 14 mg (0.98) as compared to placebo (2.69), the difference being statistically significant for both (p=0.0234 and p=0.0052, respectively).

16 How Supplied/storage And Handling ⮝

Teriflunomide Tablets, 7 mg are pale green to green colored, round, biconvex coated tablet debossed with AC and 21 on one side and plain on other side.
They are available as follows:

Bottle of 28 Tablets: NDC 69238-1303-6
Carton of 28 Tablets: NDC 69238-1303-2
(1 wallet composed of 2 folded blister cards of 14 tablets per blister card)

Teriflunomide Tablets, 14 mg are pale blue to blue colored, round, biconvex coated tablet debossed with AC and 22 on one side and plain on other side.
They are available as follows:

Bottle of 28 Tablets: NDC 69238-1304-6
Carton of 28 Tablets: NDC 69238-1304-2
(1 wallet composed of 2 folded blister cards of 14 tablets per blister card)

Store at 20 to 25 C (68 to 77 F); excursions permitted between 15 to 30 C (59 to 86 F) [see USP Controlled Room Temperature].

Principal Display Panel ⮝

Teriflunomide Tablets, 7 mg
Rx Only
Amneal Pharmaceuticals LLC

Teriflunomide Tablets, 14 mg
Rx Only
Amneal Pharmaceuticals LLC

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69238-1303 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TERIFLUNOMIDE (UNII: 1C058IKG3B) (TERIFLUNOMIDE - UNII:1C058IKG3B) TERIFLUNOMIDE 7 mg

Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 2 (UNII: L06K8R7DQK) FERRIC OXIDE YELLOW (UNII: EX438O2MRT) HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH) HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B) STARCH, CORN (UNII: O8232NY3SJ) TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Product Characteristics Color GREEN (pale green to green) Score no score Shape ROUND (Biconvex) Size 6mm Flavor Imprint Code AC;21 Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69238-1303-2 2 in 1 CARTON 10/01/2018 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product 2 NDC:69238-1303-6 28 in 1 BOTTLE; Type 0: Not a Combination Product 10/01/2018

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209613 10/01/2018

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69238-1304 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TERIFLUNOMIDE (UNII: 1C058IKG3B) (TERIFLUNOMIDE - UNII:1C058IKG3B) TERIFLUNOMIDE 14 mg

Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 2 (UNII: L06K8R7DQK) HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH) HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) SODIUM STARCH GLYCOLATE TYPE A CORN (UNII: AG9B65PV6B) STARCH, CORN (UNII: O8232NY3SJ) TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Product Characteristics Color BLUE (Pale blue to blue) Score no score Shape ROUND (Biconvex) Size 7mm Flavor Imprint Code AC;22 Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69238-1304-2 2 in 1 CARTON 10/01/2018 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product 2 NDC:69238-1304-6 28 in 1 BOTTLE; Type 0: Not a Combination Product 10/01/2018

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209613 10/01/2018

Labeler - Amneal Pharmaceuticals NY LLC (123797875)

Revised: 9/2019 Document Id: 6b8af4fc-3507-473a-b689-b6c03cf8267c 34391-3 Set id: 1f054d91-aede-4c1a-9aba-04f40d11e4d1 Version: 3 Effective Time: 20190919 Amneal Pharmaceuticals NY LLC

Warning: Hepatotoxicity And Risk Of Teratogenicity ⮝

Hepatotoxicity

Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury.

Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide [see Warnings and Precautions (5.1)]. If drug induced liver injury is suspected, discontinue teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3)]. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4)]. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide.

Risk of Teratogenicity

Teriflunomide is contraindicated for use in pregnant women and in women of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposures lower than that in humans. Exclude pregnancy before the start of treatment with teriflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during teriflunomide treatment and during an accelerated drug elimination procedure after teriflunomide treatment. Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant [see Contraindications (4), Warnings and Precautions (5.2, 5.3), Use in Specific Populations (8.1), and Clinical Pharmacology (12.3)].

16 How Supplied/storage And Handling  ⮝

Teriflunomide is available as 7 mg and 14 mg tablets.

The 14 mg tablet is a light blue to blue, biconvex, round film-coated tablet debossed with G on one side and 42 on the other side.

Each tablet contains 14 mg of teriflunomide and are supplied as follows:

NDC 68462-312-84 Carton of 28 tablets. Each carton contains two blister cards of 14 tablets.
NDC 68462-312-85 Carton of 5 tablets. Each carton contains one blister card of 5 tablets.

The 7 mg tablet is a light green to green, biconvex, round film-coated tablet debossed with G on one side and 43 on the other side.

Each tablet contains 7 mg of teriflunomide and are supplied as follows:

NDC 68462-311-84 Carton of 28 tablets. Each carton contains two blister cards of 14 tablets.
NDC 68462-311-85 Carton of 5 tablets. Each carton contains one blister card of 5 tablets.

Store at 20 to 25 C (68 to 77 F); excursions permitted to 15 to 30 C (59 to 86 F) [see USP Controlled Room Temperature].

Package/label Display Panel  ⮝

NDC 68462-312-84

Teriflunomide Tablets

14 mg-28 Tablets-Carton Label

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68462-311 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength teriflunomide (UNII: 1C058IKG3B) (teriflunomide - UNII:1C058IKG3B) teriflunomide 7 mg

Inactive Ingredients Ingredient Name Strength STARCH, CORN (UNII: O8232NY3SJ) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) TALC (UNII: 7SEV7J4R1U) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) FD&C BLUE NO. 2 (UNII: L06K8R7DQK) FERRIC OXIDE YELLOW (UNII: EX438O2MRT)

Product Characteristics Color GREEN (light green to green) Score no score Shape ROUND (biconvex) Size 6mm Flavor Imprint Code G;43 Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:68462-311-84 2 in 1 CARTON 11/16/2018 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product 2 NDC:68462-311-85 1 in 1 CARTON 11/16/2018 2 5 in 1 BLISTER PACK; Type 0: Not a Combination Product

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209663 11/16/2018

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:68462-312 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength teriflunomide (UNII: 1C058IKG3B) (teriflunomide - UNII:1C058IKG3B) teriflunomide 14 mg

Inactive Ingredients Ingredient Name Strength STARCH, CORN (UNII: O8232NY3SJ) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH) LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO) POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ) TALC (UNII: 7SEV7J4R1U) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) FD&C BLUE NO. 2 (UNII: L06K8R7DQK)

Product Characteristics Color BLUE (light blue to blue) Score no score Shape ROUND (biconvex) Size 7mm Flavor Imprint Code G;42 Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:68462-312-84 2 in 1 CARTON 11/16/2018 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product 2 NDC:68462-312-85 1 in 1 CARTON 11/16/2018 2 5 in 1 BLISTER PACK; Type 0: Not a Combination Product

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209663 11/16/2018

Labeler - Glenmark Pharmaceuticals Inc., USA (130597813)

Establishment
Name	Address	ID/FEI	Business Operations
Glenmark Pharmaceuticals Limited		862603186	MANUFACTURE(68462-311, 68462-312) , ANALYSIS(68462-311, 68462-312)

Establishment
Name	Address	ID/FEI	Business Operations
Glenmark Life Sciences Limited		860186085	API MANUFACTURE(68462-311, 68462-312)

Revised: 5/2019 Document Id: c39242c2-d869-4f78-b0f5-c6fdb6f307f2 34391-3 Set id: a07d8829-8753-476a-84fe-432c73f2c70d Version: 2 Effective Time: 20190503 Glenmark Pharmaceuticals Inc., USA

See Full Prescribing Information For Complete Boxed Warning ⮝

Hepatotoxicity
Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide and monitor ALT levels at least monthly for six months (5.1). If drug induced liver injury is suspected, discontinue teriflunomide and start accelerated elimination procedure (5.3).

Risk of Teratogenicity
Teratogenicity and embryolethality occurred in animals administered teriflunomide (5.2, 8.1). Exclude pregnancy prior to initiating teriflunomide therapy (4, 5.2, 8.1). Advise use of effective contraception in females of reproductive potential during treatment and during an accelerated drug elimination procedure (4, 5.2, 5.3, 8.1). Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant (5.2, 5.3, 8.1).

Warning: Hepatotoxicity And Risk Of Teratogenicity ⮝

Hepatotoxicity

Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Concomitant use of teriflunomide with other potentially hepatotoxic drugs may increase the risk of severe liver injury.

Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide [see Warnings and Precautions (5.1)]. If drug induced liver injury is suspected, discontinue teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3)]. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4)]. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide.

Risk of Teratogenicity
Teriflunomide is contraindicated for use in pregnant women and in women of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposures lower than that in humans. Exclude pregnancy before the start of treatment with teriflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during teriflunomide treatment and during an accelerated drug elimination procedure after teriflunomide treatment. Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant [see Contraindications (4) , Warnings and Precautions (5.2,5.3),Use in Specific Populations (8.1) , and Clinical Pharmacology (12.3)].

1 Indications And Usage ⮝

Teriflunomide tablet is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

3 Dosage Forms And Strengths ⮝

Teriflunomide tablets are available as 7 mg and 14 mg tablets.

Blue colored, pentagonal shaped, biconvex, film coated tablets, debossed with "14" on one side and "T" on other side. Each tablet contains 14 mg of teriflunomide.

Light blue colored, hexagonal shaped, biconvex, film coated tablets, debossed with "7" on one side and "T" on other side. Each tablet contains 7 mg of teriflunomide.

16 How Supplied/storage And Handling ⮝

Teriflunomide tablets are available as 7 mg and 14 mg tablets.

The 14 mg tablet is blue colored, pentagonal shaped, biconvex, film coated tablets, de bossed with "14" on one side and "T" on other side. Each tablet contains 14 mg of teriflunomide.

The 7 mg tablet is light blue colored, hexagonal shaped, biconvex, film coated tablets, debossed with "7" on one side and "T" on other side. Each tablet contains 7 mg of teriflunomide.

Teriflunomide 14 mg tablets are supplied as:

NDC 69539-033-41 Carton of 28 tablets containing 1 wallet composed of 2 folded blister cards of 14 tablets per blister card
Teriflunomide 7 mg tablets are supplied as:

NDC 69539-032-41 Carton of 28 tablets containing 1 wallet composed of 2 folded blister cards of 14 tablets per blister card
Store at 68 F to 77 F (20 C to 25 C) with excursions permitted between 59 F and 86 F (15 C and 30 C).

Package Label.principal Display Panel ⮝

Teriflunomide 14 mg - 28 (2x14) carton label:







Teriflunomide 14 mg-14s blister foil

Teriflunomide 14 mg-blister pouch









Teriflunomide 7 mg 28 (2x14)carton label







Teriflunomide 7 mg blister foil

Teriflunomide 7 mg blister pouch

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69539-032 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TERIFLUNOMIDE (UNII: 1C058IKG3B) (TERIFLUNOMIDE - UNII:1C058IKG3B) TERIFLUNOMIDE 7 mg

Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) STARCH, CORN (UNII: O8232NY3SJ) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P) MAGNESIUM STEARATE (UNII: 70097M6I30) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A) TALC (UNII: 7SEV7J4R1U) FD&C BLUE NO. 1 (UNII: H3R47K3TBD) FERRIC OXIDE YELLOW (UNII: EX438O2MRT) FD&C BLUE NO. 2 (UNII: L06K8R7DQK) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYPROMELLOSES (UNII: 3NXW29V3WO)

Product Characteristics Color BLUE Score no score Shape HEXAGON (6 sided) Size 7mm Flavor Imprint Code 7;T Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69539-032-41 2 in 1 CARTON 04/24/2019 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209623 04/24/2019

TERIFLUNOMIDE teriflunomide tablet, film coated

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69539-033 Route of Administration ORAL

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TERIFLUNOMIDE (UNII: 1C058IKG3B) (TERIFLUNOMIDE - UNII:1C058IKG3B) TERIFLUNOMIDE 14 mg

Inactive Ingredients Ingredient Name Strength LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) STARCH, CORN (UNII: O8232NY3SJ) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) HYDROXYPROPYL CELLULOSE (UNII: RFW2ET671P) MAGNESIUM STEARATE (UNII: 70097M6I30) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A) FD&C BLUE NO. 2 (UNII: L06K8R7DQK) FERRIC OXIDE YELLOW (UNII: EX438O2MRT) SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYPROMELLOSES (UNII: 3NXW29V3WO)

Product Characteristics Color BLUE Score no score Shape PENTAGON (5 sided) Size 7mm Flavor Imprint Code 14;T Contains

Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69539-033-41 2 in 1 CARTON 04/24/2019 1 14 in 1 BLISTER PACK; Type 0: Not a Combination Product

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA209623 04/24/2019

Labeler - MSN LABORATORIES PRIVATE LIMITED (650786952)

Establishment
Name	Address	ID/FEI	Business Operations
MSN LABORATORIES PRIVATE LIMITED		650786952	ANALYSIS(69539-032, 69539-033) , MANUFACTURE(69539-032, 69539-033)

Revised: 5/2019 Document Id: 8bcde450-65e2-4a5d-b062-9f4858e4b319 34391-3 Set id: 63ba28ef-5055-461a-99ef-c49e8ece4b54 Version: 5 Effective Time: 20190503 MSN LABORATORIES PRIVATE LIMITED